Contraception

Cyclica has received a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to new therapeutic options for multiple low-data biological targets.   The end goal is to expand the range of accessible non-hormonal contraceptive choices for women in developing countries.  The CAD$2.4M ($1.8M) grant enables Cyclica to focus on […]

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer  Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens.   However, there was also controversy as researchers faced a backlash from the National Institute […]

The first and only oral contraception containing a new, synthetic version of a naturally occurring oestrogen has been launched in the UK.  Gedeon Richter’s Drovelis (14.2mg estetrol [E4] plus 3mg drospirenone [DRSP]) as a combined oral contraceptive is now available.  The company cautions that any decision to prescribe E4/DRSP should take into consideration the individual […]

Gedeon Richter has become marketing authorisation holder for Evra, a once-weekly contraception for women of fertile age, which they say is the first and only transdermal contraceptive patch licenced in the UK.   Tamas Neubauer, Managing Director of UK and Ireland at Gedeon Richter, believes that the addition of a patch to their existing contraceptive delivery methods such as oral contraceptives, […]